-
Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future
Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future Editor’s Note: From September 22nd to 24th, 2024, the 20th International Esophageal Cancer Conference (ISDE) took place in Edinburgh, Scotland. The Neo-AEGIS study, which compared the efficacy of perioperative chemotherapy with the CROSS regimen (preoperative chemotherapy combined with radiotherapy) in…
-
ISDE 2024 | Groundbreaking: Prehabilitation Transforms Borderline Resectable Esophageal Cancer Patients into Surgical Candidates
The 20th International Society for Diseases of the Esophagus (ISDE) conference took place in Edinburgh, Scotland, from September 22nd to 24th, 2024. At the conference, a study by Dr. Krishna Moorthy from the Royal College of Surgeons in the UK on whether prehabilitation can increase the surgical opportunities for esophageal cancer patients was selected for…
-
Integrative Medicine Shines at CACA: Dr. Liu Hong Outlines New Horizons in Esophageal Cancer Treatment
From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. The conference, under the theme “Winning in Integration for Cancer Prevention and Treatment,” gathered the latest research developments and clinical experiences from experts in esophageal cancer…
-
One Health: United Efforts to Combat Resistance丨The Second One Health Antimicrobial Resistance Control Conference Kicks Off in Hangzho
Opening Ceremony On this beautiful autumn day in Hangzhou, the Second One Health Antimicrobial Resistance Control Conference officially kicked off. The conference began with a warm welcome from the Executive…
-
Advancing Liver Cancer Treatment: Insights from Professor Tim Meyer
In a recent discussion, Professor Tim Meyer highlighted the importance of multidisciplinary care in liver cancer treatment. As systemic therapies evolve, including combinations of tyrosine kinase inhibitors and immunotherapy, there’s…
-
Breaking New Ground in T-Cell Lymphoma Treatment: Insights from Dr. Swaminathan P iyer Iyer and Dr. Lihua Qiu
In a recent discussion, Dr. Swaminathan Iyer from MD Anderson Cancer Center and Dr. Lihua Qiu highlighted the evolving landscape of peripheral T-cell lymphoma (PTCL) treatment. They emphasized the importance of cross-border collaboration to tackle the complexities of PTCL and the promising advancements in therapies such as PI3K inhibitors, EZH2 inhibitors, and JAK1 inhibitors. With…
-
CSCO 2024 Visionary: Dr. Jun Zhou Illuminates the Path Forward for Biliary Tract Cancer Treatment
From September 25 to 29, 2024, the highly anticipated 27th National Clinical Oncology Conference and CSCO Annual Meeting was successfully held in Xiamen. This prestigious event brought together top experts in the field of oncology from across China, focusing on standardized pathways for diagnosis and treatment of malignant tumors and exploring the latest frontiers. During…
-
Breaking Ground in STS Treatment: Dr. Yuhong Zhou Champions Anti-Angiogenic TKIs at CSCO 2024
Soft tissue sarcoma (STS) is a highly heterogeneous group of tumors with complex pathology, and the benefits of first-line chemotherapy, primarily anthracycline-based, are limited. As a result, patient prognosis remains poor overall. In recent years, anti-angiogenic tyrosine kinase inhibitors (TKIs) have emerged as a promising option for second- and later-line treatments, with potential for expansion…
Connecting Medical Expertise through Media